Story thread · 2 reports / 2 sources

With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems

genengnews.com · 6dShare

BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression and immune evasion and is highly expressed in anywhere from 60% of solid tumor samples up to 93%, according to past studies cited by BrainChild Bio. The post With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems appeared first on GEN - Genetic Engineering and Biotechnology News .

First report: BrainChild Bio raises over $100 million to treat kids’ cancers with CAR-Ts — cen.acs.org, 6d